Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Cytokinetics (CYTK)

Cytokinetics (CYTK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,319,015
  • Shares Outstanding, K 85,652
  • Annual Sales, $ 70,430 K
  • Annual Income, $ -215,310 K
  • 60-Month Beta 1.22
  • Price/Sales 46.51
  • Price/Cash Flow N/A
  • Price/Book 28.12
Trade CYTK with:

Options Overview Details

View History
  • Implied Volatility 80.86% ( -3.85%)
  • Historical Volatility 72.77%
  • IV Percentile 75%
  • IV Rank 23.19%
  • IV High 185.10% on 07/08/21
  • IV Low 49.39% on 08/31/21
  • Put/Call Vol Ratio 2.00
  • Today's Volume 3
  • Volume Avg (30-Day) 293
  • Put/Call OI Ratio 0.13
  • Today's Open Interest 10,070
  • Open Int (30-Day) 10,654

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -1.04
  • Number of Estimates 6
  • High Estimate -0.98
  • Low Estimate -1.12
  • Prior Year -0.86
  • Growth Rate Est. (year over year) -20.93%

Price Performance

See More
Period Period Low Period High Performance
1-Month
33.60 +15.33%
on 04/28/22
44.85 -13.60%
on 05/16/22
+2.25 (+6.16%)
since 04/25/22
3-Month
33.10 +17.07%
on 03/16/22
44.85 -13.60%
on 05/16/22
+3.73 (+10.65%)
since 02/25/22
52-Week
17.72 +118.68%
on 07/14/21
47.90 -19.10%
on 12/30/21
+16.42 (+73.53%)
since 05/25/21

Most Recent Stories

More News
Cytokinetics Announces Data From REDWOOD-HCM OLE and GALACTIC-HF Presented as Late Breaking Science Presentations at the European Society of Cardiology Heart Failure 2022 Congress

Data from Up to Six Months of Treatment with Aficamten Show Significant and Sustained Reductions in LVOT Gradients with Improvements in Functional Class,...

CYTK : 38.75 (+1.33%)
Why Orphan Drug Designation Offers Several Benefits

Palm Beach, FL – May 18, 2022 – FinancialNewsMedia.com News Commentary – The U.S. FDA prioritizes developing new treatments for rare diseases with the ability to grant Orphan Drug Designation. Here...

CRDL : 1.1400 (+6.05%)
CRDL.TO : 1.47 (+7.30%)
ABBV : 151.96 (+1.91%)
CRSP : 54.55 (+4.14%)
CYTK : 38.75 (+1.33%)
Cytokinetics and the ALS Association Renew Partnership to Advance the Fight Against ALS

SOUTH SAN FRANCISCO, Calif., AND WASHINGTON, May 18, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) and The ALS Association today...

CYTK : 38.75 (+1.33%)
Cytokinetics to Participate in the 2022 H.C. Wainwright Global Life Sciences Conference

SOUTH SAN FRANCISCO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President...

CYTK : 38.75 (+1.33%)
Cytokinetics Provides Regulatory Update Related to New Drug Application for Omecamtiv Mecarbil

FDA Plans to Convene Advisory Committee Meeting...

CYTK : 38.75 (+1.33%)
Cytokinetics Announces Three Upcoming Presentations at the European Society of Cardiology Heart Failure 2022 Congress

SOUTH SAN FRANCISCO, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three Late-Breaking Science...

CYTK : 38.75 (+1.33%)
Cytokinetics (CYTK) Reports Q1 Loss, Misses Revenue Estimates

Cytokinetics (CYTK) delivered earnings and revenue surprises of -9.68% and 77.53%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

CYTK : 38.75 (+1.33%)
CRMD : 3.24 (-0.31%)
Cytokinetics Reports First Quarter 2022 Financial Results

Initial Data from REDWOOD-HCM OLE, the Open Label Extension Study of Aficamten, to be Presented at Heart Failure 2022 on May 23, 2022 Continued Launch...

CYTK : 38.75 (+1.33%)
Cytokinetics to Hold Annual Meeting of Stockholders

SOUTH SAN FRANCISCO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that its Annual Meeting of...

CYTK : 38.75 (+1.33%)
Strength Seen in Cytokinetics (CYTK): Can Its 11.5% Jump Turn into More Strength?

Cytokinetics (CYTK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the...

CYTK : 38.75 (+1.33%)
TELA : 6.59 (-1.79%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology...

See More

Key Turning Points

3rd Resistance Point 41.69
2nd Resistance Point 40.69
1st Resistance Point 39.72
Last Price 38.75
1st Support Level 37.76
2nd Support Level 36.76
3rd Support Level 35.79

See More

52-Week High 47.90
Last Price 38.75
Fibonacci 61.8% 36.37
Fibonacci 50% 32.81
Fibonacci 38.2% 29.25
52-Week Low 17.72

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar